Blue Jet Health (BLUEJET)
FairStock Score: 46/100 — MIXED
Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹584.5 |
| Market Cap | ₹10,139.05 Cr |
| P/E Ratio | 43.1 |
| ROCE | 39.75% |
| ROE | 25.91% |
| Dividend Yield | 0.2% |
| Profit Growth | -14.16% |
| Debt/Equity | 0.03 |
| Sales Growth | -19.26% |
| Free Cash Flow | ₹10.58 Cr |
| Promoter Holding | 79.81% |
| 52-Week Range | ₹325 — ₹688.5 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹78.4 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Blue Jet Health has the financial fingerprints of a quality compounder. Return on equity of 25.91% and ROCE of 39.75% are outstanding, especially with debt/equity of just 0.02. This kind of high-return, near-debtless pharmaceutical business usually reflects an economic moat in specialised products or processes; Graham would admire the balance-sheet discipline. Sales grew 20.56% and profits rose 25.06%, so the business is still expanding at a healthy clip. Promoters own 79.81%, so owners have skin in the game. The Piotroski F-score of 6/9 and Altman Z-score of 5.35 reinforce that the company is financially safe. However, none of that gives me permission to overpay. At ₹413.75, the stock quotes at 23.95 times earnings and 6.33 times book value. Graham's number, a conservative estimate of intrinsic worth, is just ₹157.74, so the margin of safety is -156.94%. In plain words, I would be relying entirely on the growth story continuing; there is no asset-earnings cushion at this price. The dividend yield of 0.30% does not compensate for that risk. The latest quarter's ₹192 Cr sales and ₹40 Cr profit look good, but free cash flow of only ₹11 Cr is a warning: reported profits are not fully converting into cash. I would probe that gap before trusting earnings quality. The negative EV/EBITDA (-7.27) and the absurd DCF value of ₹0.35 are inconsistent with a profitable operating company, so I cannot give those numbers any weight. This is a fine fast grower, but at this price it fails my margin-of-safety test. I will wait for a much better price or demonstrated improvement in cash generation.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer